Back to results

Washington University in St. Louis

MicroRNAs in ALS: Defining Cell-Type Specific Expression, Developing Methods to Modulate MicroRNAs in vivo, and Identifying Novel Therapeutic Targets

Abstract

dc:description.abstract

<p>Amyotrophic lateral sclerosis (ALS) is an adult-onset, fatal neuromuscular disease with no adequate therapies. MicroRNAs (miRNAs) are dysregulated in a variety of disease states, suggesting that this newly discovered class of gene expression repressors may be viable therapeutic targets. A microarray of miRNA changes in ALS model SOD1G93A rodents identified 12 miRNAs as significantly changed. Six miRNAs tested in human ALS tissues were confirmed increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords. Generation of mice that express a GFP-tagged miRNA processing protein behind cell-type specific promoters allowed for the identification of miRNA expression patterns in various neural cell types. From this information, we focused on the role of miR-155 on glial cells and particularly on neuroinflammatory pathways in ALS. miR-155, miR-146a, and miR-142-5p were upregulated beginning in a mid-disease stage and were highly correlated with one another and with various neuroinflammatory mediators. To test miRNA inhibition in the central nervous system as a potential novel therapeutic, we developed oligonucleotide-based miRNA inhibitors (anti-miRs) that could inhibit miRNAs throughout the central nervous system and in the periphery. Anti-miR-155 caused global derepression of targets in peritoneal macrophages and, following intraventricular delivery, demonstrated widespread functional distribution in the brain and spinal cord. After treating SOD1G93A mice with anti-miR-155, we significantly extended survival by 10 days and disease duration by 15 days (38%) while a scrambled control anti-miR did not significantly improve survival or disease duration. Therefore, antisense oligonucleotides may be used to successfully inhibit miRNAs throughout the brain and spinal cord, and miR-155 is a promising new therapeutic target for human ALS.</p>

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (PhD)
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Biology and Biomedical Sciences: Neurosciences
Year dc:date.available
2014

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Koval, Erica Danielle
Contributors dc:contributor
  • Timothy M Miller

Subjects

dc:subject × 4

Rights

Language dc:language
English (en)

Identifiers

dc:identifier.*
OAI identifier oai:identifier
oai:openscholarship.wustl.edu:etd-2313

Chain of custody

source
Harvested from
Washington University in St. Louis
Base URL
openscholarship.wustl.edu/do/oai/
Last updated
2026-07-24
Source record
OAI-PMH GetRecord
citation

Koval, Erica Danielle. MicroRNAs in ALS: Defining Cell-Type Specific Expression, Developing Methods to Modulate MicroRNAs in vivo, and Identifying Novel Therapeutic Targets. Dissertation thesis, 2014. https://openscholarship.wustl.edu/etd/1313